Phase I dose-escalation trials with HIF-2 alpha inhibitors in combination with nivolumab or cabozantinib are ongoing in patients with ccRCC, with planned completion dates in November 2022 [42]. Here, EPAS1 is linked to nonpapillary renal cell carcinoma.